Celsion’s extensive oncology pipeline represents a comprehensive, integrated portfolio of targeted therapeutic agents, encompassing chemotherapy, immunotherapy, and RNA therapy.
ThermoDox®, Celsion’s lead product candidate, incorporates Lyso-Thermosenstive Liposomal Doxorubicin (LTLDs), a unique liposomal technology that allows for the triggered release of a drug payload through low temperature (just above body temperature) heat activation.
TheraPlas™ is a versatile technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers and is uniquely capable of providing cell transfection capability for double-stranded DNA plasmids and large therapeutic RNA segments such as mRNA.
TheraSilence™ is a versatile technology platform focused on delivering synthetically generated small inhibitory RNAs (siRNAs), microRNAs, microRNA mimics, and related molecules that can regulate protein expression by exploiting endogenous cell mechanisms.
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company’s lead program is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and Phase II development for the treatment of recurrent chest wall breast cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has three platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence.